Aurora Spine Surpasses 1,500 Successful Surgeries Using DEXA-C(TM)
MWN-AI** Summary
Aurora Spine Corporation, a leader in spinal implant technology, has announced a significant milestone: over 1,500 successful surgeries utilizing its innovative DEXA-C™ system. This achievement reflects the growing acceptance and reliability of the DEXA Technology™ platform in cervical spine procedures across the United States. Aurora’s proprietary technology is distinguished as the world’s first spinal implant platform designed to match a patient's bone density, accommodating a range of conditions from normal to osteoporotic bone.
Designed with an open, porous structure, DEXA implants foster osseointegration and mimic the architecture of human bone, ensuring compatibility and stability. Trent Northcutt, President and CEO of Aurora Spine, emphasized the importance of this technology, stating that DEXA-C™ allows surgeons to consider bone quality when selecting implants, ultimately improving patient outcomes.
Following this success, Aurora is set to expand its DEXA line with the DEXA-L™, a new Anterior Lumbar Interbody Fusion (ALIF) system, scheduled for launch in Q4 2025. This upcoming product, like DEXA-C™, targets the challenges faced in spinal fusion surgeries, particularly for patients with varied bone densities, including those with osteoporosis.
Historically, spinal implants have been optimized for individuals with healthy bone stock, leading to inadequate performance for those with lower density. DEXA Technology™ addresses these shortcomings by providing tailored solutions that enhance the standards of care for diverse patient populations.
Aurora Spine is committed to developing personalized spinal solutions and expanding its product portfolio, which now includes cervical, lumbar, and sacroiliac fusion systems. For further details, visit their website at www.aurora-spine.com.
MWN-AI** Analysis
Aurora Spine Corporation's recent milestone of surpassing 1,500 successful surgeries using its DEXA-C™ system represents a significant achievement in the spinal implant market, especially considering the current trend towards personalized medical solutions. This accomplishment highlights not only the technology's effectiveness but also the growing acceptance of DEXA Technology™ among healthcare providers, which is essential for attracting investors.
As the company prepares to launch the DEXA-L™ product later this year, it stands poised to capture an expanding market segment that focuses on varied bone densities, particularly among osteoporosis patients. With traditional spinal implants often falling short for these populations, Aurora’s innovative approach positions them as a frontrunner in addressing this clinical gap. Investors should take note that the forthcoming launch could catalyze increased sales momentum and solidify Aurora’s market presence further.
Additionally, the recent recognition received with the Best Technology in Spine Award underscores the credibility of both the product and the company, lending additional support to its growth narrative. This recognition can enhance trust with medical professionals, ultimately translating to increased surgical adoption rates.
Investors should consider Aurora Spine as a compelling opportunity, particularly given the growing market for bone health solutions amidst demographic shifts towards an aging population. However, it's important to remember the inherent risks associated with clinical technologies, including regulatory changes and potential competition as the market evolves.
In conclusion, for investors considering Aurora Spine's stock, the combination of their proven technology, upcoming product launches, and market differentiation provides a promising outlook. Monitoring the trajectory of DEXA Technology™ adoption and sales figures in the upcoming quarters will be critical for assessing future investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
CARLSBAD, CALIFORNIA, June 16, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF) , a leader in innovative spinal implant technology, is proud to announce that its DEXA-C™ system has now been successfully used in more than 1,500 cervical spine procedures across the United States. This milestone underscores the ongoing adoption and trusted performance of the DEXA Technology™ platform, which was honored with the Best Technology in Spine Award .
Aurora’s proprietary DEXA Technology™ is the world’s first spinal implant platform intentionally engineered to match a patient’s bone density across the entire BMD continuum , including normal, osteopenic, and osteoporotic bone. Each implant is designed with an open, porous structure that promotes osseointegration and vascularization , and mimics the lattice architecture of human cancellous bone — resulting in a similar modulus of elasticity and better biomechanical compatibility.
“DEXA-C™ provides surgeons with the first tool that truly puts bone quality at the center of implant selection,” said Trent Northcutt, President and CEO of Aurora Spine. “With over 1,500 successful surgeries behind us, the data is clear: this technology improves outcomes. And now, we’re ready to take it even further as we build out our sales efforts for this platform technology and prepare launch for our second DEXA Technology-enabled product the DEXA-L, which will be rolled out later this year.”
Aurora Spine is excited to announce the upcoming Q4 2025 launch of DEXA-L™ , a standalone Anterior Lumbar Interbody Fusion (ALIF) system built on the same award-winning DEXA platform. Like DEXA-C™, the DEXA-L™ implant is designed to address the challenges of spinal fusion in patients with varying bone densities — especially those with osteoporosis.
For decades, spinal implants were primarily developed for patients with healthy bone stock. However, these implants have demonstrated reduced performance in patients with low bone density , where traditional designs may lack sufficient bone-implant contact and fail to achieve long-term fixation . DEXA Technology™ directly addresses this clinical gap , offering a smart, density-matched solution for today’s diverse patient population.
Aurora continues its mission to bring personalized spine solutions to market, with a growing DEXA portfolio that includes cervical, lumbar, and sacroiliac fusion systems.
For more information on DEXA Technology™ and Aurora’s full product line, visit www.aurora-spine.com .
About Aurora Spine
Aurora Spine is focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies. Additional information can be accessed at www.aurora-spine.com. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurora Spine, including, without limitation, those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Information" in Aurora Spine's final prospectus (collectively, "forward-looking information"). Forward-looking information in this news release includes information concerning the proposed use and success of the company’s products in surgical procedures. Aurora Spine cautions investors of Aurora Spine's securities about important factors that could cause Aurora Spine's actual results to differ materially from those projected in any forward-looking statements included in this news release. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ unilaterally from those expressed in such forward-looking statements. No assurance can be given that the expectations set out herein will prove to be correct and, accordingly, prospective investors should not place undue reliance on these forward-looking statements. These statements speak only as of the date of this press release and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances.
Company Contacts: Aurora Spine Corporation
Trent Northcutt
?President and Chief Executive Officer
?(760) 424-2004
Chad Clouse
?Chief Financial Officer
?(760) 424-2004
? www.aurora-spine.com
Investor Contact:
Adam Lowensteiner
??Lytham Partners
??(646) 829-9702
Email: asapf@lythampartners.com
FAQ**
How does the successful implementation of the DEXA-C™ system in over 1,500 procedures strengthen the market position of Aurora Spine Corporation ASG:CC in the spinal implant industry?
What specific challenges in spinal fusion for patients with low bone density does the DEXA Technology™ address, and how might this influence investor confidence in Aurora Spine Corporation ASG:CC?
With the anticipated Q4 2025 launch of DEXA-L™, what sales strategies does Aurora Spine Corporation ASG:CC plan to deploy to maximize market penetration and expand its DEXA portfolio?
In light of the forward-looking statements issued by Aurora Spine Corporation ASG:CC, what are the key risk factors that potential investors should consider before investing in the company?
**MWN-AI FAQ is based on asking OpenAI questions about Aurora Spine Corp (OTC: ASAPF).
NASDAQ: ASAPF
ASAPF Trading
6.6% G/L:
$0.21 Last:
2,600 Volume:
$0.2059 Open:
